Amgen Inc
(FRA:AMG)
€
283.45
-18.25 (-6.05%)
Market Cap: 150.69 Bil
Enterprise Value: 198.90 Bil
PE Ratio: 38.26
PB Ratio: 21.34
GF Score: 90/100 
Amgen Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020 / 04:35PM GMT
Release Date Price:
€206.9
(-2.06%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome, everyone. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA, and welcoming you to the London Health Care Conference. I also have asked Aspen Mori from my team with me as well. There are questions via the Veracast system, so feel free to log those in. And we are thrilled today to have Amgen presenting. And speaking on behalf of Amgen, we have CFO, Peter Griffith. We have to -- also have Arvind Sood from the IR team. Welcome, guys.
Peter H. Griffith
Amgen Inc. - Executive VP & CFO
Thank you, Geoff.
Arvind Sood
Amgen Inc. - VP of IR
Thank you.
Peter H. Griffith
Amgen Inc. - Executive VP & CFO
Thank you to AML, too. Thank you for having us.
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Of course, yes. So you guys are going to go through some slides first.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers